- The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's LLY rheumatoid arthritis drug for an initial portfolio of preferred medications to treat COVID-19, reports Reuters.
- The selection of drugs is part of the E.U. Strategy on COVID-19 therapeutics, launched in May.
- Top picks include Eli Lilly - Incyte Corporation's INCY Olumiant for hospitalized COVID-19 patients on oxygen, as well as new antibody drugs for early-stage disease from Regeneron Pharmaceuticals Inc REGN, Eli Lilly, Celltrion, and GlaxoSmithKline plc GSK - Vir Biotechnology Inc VIR.
- The Commission reiterated it would draw up a portfolio of at least ten potential COVID-19 therapeutics.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.